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Summary: A spectrometric modification of the determination of total bilirubin with the Du Pont ACA is described.
Accuracy, precision and standardization problems are discussed in comparison with the earlier published diazo
modification, as well as other techniques well known in the field of neonatal chemistry.
Spektrometrische Version der Bestimmung von Gesamt-Bilirubin mit dem Du Pont ACA unter Berücksichtigung
von Seren Neugeborener
Zusammenfassung: Eine spektrometrische Modifikation der Bestimmung von GesamMJilirubin mit dem Du Pont
ACA wird beschrieben. Richtigkeit, Präzision und Standardisierungsprobleme werden im Vergleich mit der früher
veröffentlichten Modifikation der Diazo-Methode wie auch anderen für Bestimmungen bei Neugeborenen bekannten
Methoden diskutiert.
Introduction
In a previous study we described how the Du Pont
Automatic Clinical Analyzer (ACA), TBIL method
could be modified in order to make the method suitable
for determining total bilirubin in neonatal serum (1). We
reported that this modification, called BBIL, worked
satisfactorily in the opinion of the clinicians working in
our hospital. However, from a clinical chemical point of
view we had certain reservations. As we have already
mentioned the problem of accuracy was not completely
solved (hemoglobin interference). Furthermore, we had
the impression that the precision with the ACA could
be improved, and finally the correlation study some-
times showed differences that could riot be explained
very easily. Therefore we decided to study the "state
of the art" for the determination of total bilirubin in
sera of neonates. In general, there are two ways by
which total bilirubin can be determined:
1. spectrometric by measuring the absorbance of the
bilirubin colour at about the peak wavelength, and
2. by means of the diazo reaction.
The advantage of the spectrometric method is its speed
and ease. However, the advantage of the diazo reaction
is a higher sensitivity and specificity.
For the majority of samples coming from neonates one
is concerned with elevated unconjugated bilirubin
levels. In these samples turbidity and interfering
goloured components are usually absent. These reasons
and the simplicity of the technique have led to the
popularity of the spectrometric method for measuring
the bilirubin content of neonatal serum. Because of this
fact, it seemed worthwhile to study the possibilities of
the ACA with respect to a spectrometric modification,
in addition to the ACA diazo modification already
described.
Since empty packs (ABS packs) are used in the ACA
as a functional check of the system (e. g. sample dilution
and absorbance reading), it should be possible to use
these packs for a spectrometric method for determining
bilirubin concentrations.
Furthermore, the first ACA method for estimating total
bilirubin had been comparable to our proposed proce-
dure. We divided the study into four parts i. e.
1. the development of the ACA spectrometric method,
2. the interference of hemoglobin with the techniques
used,
3. the estimation of the precision of these techniques,
4. the standardization of the method.
Materials and Methods
Equipment
Du Pont Automatic Clinical Analyzer (ACA). By means of the
Computer II the spectrometric method (NBIL) was laced in
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channel 62. For a further description the reader is referred to
our earlier publication (1) or to the manufacturer.
Beckman DU-2 spectrophotometer. This well known instrument
was checked regularly according to Rand (2) with respect to
wavelength (didymium) and absorbance (cobalt sulphate).
Materials
ABS packs. The pack header code was changed by wiping off
one black bar. As a result of this a new method was "developed".
Solid bilirubin was purchased as a rule from £. Merck Co,
catalogue number 24519.
Furthermore we used the standard reference material, SRM 916
from the National Bureau of Standards.
Human albumin solution (200 g/1, salt-poor) was obtained from
Institut Merieux S. A. (France).
The materials used for the methods si Hertz (3)i Richterich (4)
and Michaelsson (5) were from E. Merck Co or J. T. Baker
Chemical Co.
Commercial sera. The reader is referred to table 3.
Methods
The preparation of bilirubin standards and hemoglobin solutions
was described earlier (1).
The methods of Hertz (3), Richterich (4) and Michaelsson (5)
were used as described in the original publications.
The Boehringer technique (Test-Combination Bilirubin, DPD-
method, cat. no. 123943) was applied according to the instruc-
tions of the manufacturer.
Results
As we mentioned in the Introduction it should be
possible to develop a spectrometric method in the ACA
system. Simply by diluting a sample with phosphate
buffer 0.15 mol/1, pH = 7.8 (already present in the
system) in an empty pack, it is possible to measure an
absorbance (filter 452 nm), which can be related to the
bilirubin content of the sample.
Correction for hemoglobin can be done by measuring
the absorbance either at 540 or 577 nm, because at
these wavelengths the absorbances of hemoglobin are
comparable to the absorbance at 452 nm.
We did our experiments with both combinations
452-540 nm and 452-577 nm. Because of the better
precision, we chose the combination 452-540 nm.
Figure 1 shows the calibration graph of the method,
which we called NBIL. Each point represents the mean
of six samples.
The study of the hemoglobin interference problem was
performed as described earlier (1) with one addition: we
also included blood additions in which a certain part
was assumed to be "fetal" hemoglobin.
These samples were obtained by lysing blood clots from
neonatal specimens. No difference was found to exist
between the "adult" and the "fetal" additions. The
results obtained for spiking with "adult" hemoglobin
are shown in figure 2.
The same technique was applied in the measurement of
the interference of hemoglobin with two other techniques.
These results are also shown in figure 2.
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Fig. 1. Calibration graph of the ACA-NBIL method. Each point
is the average of six measurements.
400
^300
c
5
Ξ3
1100
100 200
Hemoglobin
300 400
Fig. 2. The interference of hemoglobin with the ACA-NBIL
method (I), the Michaelsson technique (2) and the
Richterich technique (3).
A comparison of the precision for a number of methods
was then made. We estimated the "within-run" and the
"day-to-day" precision at two levels.
In table 1 all results are tabulated.
At this point we found the spectrometric modification
to be comparable in performance with the diazo modifica-
tion. Therefore we focussed our attention more on this
method.
We determined the recovery of bilirubin standards added
to patient samples. Because of the small residual volumes
of the samples (neonatal sera!) we decided to calculate
the recovery data on the basis of the weights of the
standard and patient sera. As an average value for the
density of serum we used 1.026 kg/1 (6). We found with
29 patient samples an average value of 101% for the
recovery (standard deviation 6%).
The correlation study for peripheral blood was done
with two other techniques: a spectrometric technique
described by Richterich (4), and the well-established
Michaelsson diazo method (5). Figure 3 shows the
comparison with the Richterich method.
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Tab. 1. Precision data.
Method Sample
Within-run precision, n =
ACA-NBIL 20 μΐ
ACA-NBIL 60 μΐ
ACA-BBIL 60 μΐ
Richterich (4) 50 μΐ
Hertz (3) 50 μΐ
Michaelsson (S) 50 μΐ
Boehringer 40 μΐ
Ictometer 20 μΐ
Low value
Average CV
[μηιοΙ/11 \%\
20
109
108
87
129
135
76
65
104
2.2
1.0
5.2
2.3
1.9
6.4
4.4
1.6
High value
Average CV
[Mmol/l] [%]
298
315
263
350
361
214
214
347
0.7
0.5
2.9
1.5
2.3
4.9
2.2
0.8
Day-to-day precision, η = 20
ACA-NBIL
ACA-BBIL
Hertz (3)
Michaelsson (5)
Boehringer
Ictometer
20 μΐ
60 μΐ
50 μΐ
50 μΐ
40 μΐ
20 μΐ
66
77
81
82
67
106
5.8
7.2
6.4
5.9
5.8
2.9
242
246
238
257
233
260
2.3
3.7
2.7
3.5
2.4
2.6
300
1200
.i± 1DO
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Fig. 4. Split sample comparison between the "NBIL" (y-axis)
and the Michaelsson technique (x-axis) for peripheral
blood (neonatal sera).
The straight line represents the "ideal" correlation,
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Fig. 3. Split sample comparison between the "NBIL" (y-axis)
and the Richterich technique (x-axis) (neonatal sera).
The straight line represents the "ideal'* correlation.
The comparison with the Michaelsson technique was
split into two parts. In total we compared 106 samples,
38 sera coining from babies receiving phototherapy,
and 68 sera from babies without phototherapy. Figure 4
shows the correlation for all specimens. The regression
equations of the two sets of specimens are given in
table 2.
We also performed a correlation study for umbilical cord
specimens. In figure 5 the results of the comparison be-
tween the NBIL and the Michaelsson technique are
shown.
In all experiments the results were obtained on the
basis of a calibration with bilirubin enriched sera. In
practice this is a rather cumbersome method. It is known
that the standardization of the bilirubin determination
is a difficult problem. The differences in standardization
Tab. 2. Statistical data.
L ACA-NBIL vs. Richterich, peripheral blood
2. ACA-NBIL vs, Michaelsson, without phototherapy
3. ACA-NBIL vs- Michaelsson, with phototherapy
4. ACA-NBIL vs, Michaelsson, peripheral blood (total 2 + 3)
5. ACA-NBIL vs, Michaelsson, umbilical cord blood
1.
2.
3.
4.
5.
Regression
equation
„
(y on x)
y = 0.92x + 5
y * 0,80 χ + 34
y = 0,82 χ + 31
y = 0.85 χ + 26
y=1.10x + 1
Correla-
tion
coeffi-
cient
r
0.99
0,93
0,92
0.94
0.93
Number
of
determi-
nations
n
40
66
39
105
43
Average
X
I/miol/1]
194
162
169
166
29
Average
y
(μιηοΐ/ΐ]
184
161
170
164
26
50
I 40ε
I 30
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Fig. 5. Split sample comparison between the "NBIL" (y-axis)
and the Michaelsson technique (x-axis) for cord blood.
The straight line represents the "ideal" correlation.
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can be caused by incomplete dissolution of the solid
bilirubin and/or the presence of compounds which
interfere with the diazo coupling reaction»
Therefore we decided to simplify the preparation of the
standard sera. The protein base was changed to human
albumin 50 g/1 instead of human sera. This solution is
more constant and no check on the colour is needed,
Secondly, we studied the possibility of using cortlhletciai
sera in calibrating the ACA. In fact we use two Ways of
determining total bilirubin L e» the "adult" Way (tBIL)
and the "neonatal" way (NBIL). In pf actice this means
that at regular intervals (to be determined by the labo-
ratory) the ACA must be calibrated, owing to the
arrival of new lotnumbers of packs. We studied 11
commercial sera divided into two concentration ranges:
a low level between 50 and 200 /zmol/l and a high level
between 300 and 400 μιηοΐ/ΐ.
The details of the commercial sera are presented in
table 3. Figure 6 shows the comparison of the ACA
values against the assigned bottle values for the commet-
cial sera.
The ACA was calibrated with bilifubin in human
albumin (50 g/1). Solid bilirubin was bought from Merck.
We compared this product with bilirubin from the
National Bureau of Standards (Standard Reference
Material, S. R. M. 916) and found as molar absorp-
tivities (1 · mol"1 · cm"1) in chloroform:61,500 for
Tab. 3. Description of commercial sera used.
tQO
< 300
Name
Monitrol II
Calibrate 2
Calibrate 3
Wellcomtrol 2
Baker Bilirubin
Standard
SMAC Control
Versatol
Pediatric
Q-PAK Bilirubin
Control ·
Precibil
Bilirubin Control
Wellcomtrol 3
Manufacturer
Dade
General
Diagnostics
General
Diagnostics
Wellcome
Baker
Technicon
General
Diagnostics
Hyland
Boehringer
Dade
Wellcome
Kind of
protein
base
Human
serum
Human
serum
Human
serum
Horse
serum
Bovine
albumin
Bovine
serum
Human
serum
Human
serum
Human
serum
Human
albumin
Bovine
serum
Assigned
value (only
Jendrassik*
Grof)
(Mmol/1]
60, 62 and 64
53
79
99
136
173
296
352 · ·
354
357
374
3
g 200
c
Jo
S 10Q
0 100 200 300 MO
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Fig. 6» Graph representing the results obtained with commercial
sera
x^axis: data given by the manufacturer
y-axis: ACA-results, ο = TBIL, Δ - NBIL.
the Merck product and 62,100 for the N.B.S. product
respectively. Furthermore we estimated the molar
absorptivity of the azobuirubin by theJendrassik-Grof
reaction. The method we used is the one recommended
by the Dutch Standardization Committee on Clinical
Chemistry and is the same as described byDoumas et al
(7). The coefficients (1 · mol"1 · cm"1) were 72,200 for
the Merck product arid 71,700 for the S.R.M. 916. We
found these values suitable for the calibration of the
TBIL and the NBIL method (12).
Discussion
The literature on the determination of bilirubin is very
extensive. A comprehensive survey of the available
literature can be found in the publications of Hertz and
Dybkaer (3,11). In general a preference exists for the
determination with the help of the diazo reaction (7).
One exception concerns the neonatal field.
Because of the absence of disturbing factors the serum
matrix with respect to bilirubin is well defined in
neonatal sera; this has resulted in the development of
many spectrometric methods. Speed and simplicity are
the reasons for the wide popularity of these methods.
We started the study of the determination of total
bilirubin on the ACA with neonatal sera by modifying
the existing method (TBIL) as we described earlier
(BBIL). The method worked well, but because of the
reasons mentioned in the Introduction, we wished to
know if some kind of a spectrometric modification
could be Worked out in the ACA; and if so, whether the
method would be comparable or better in performance
with respect to the BBIL. The present study therefore
describes the development of a spectrometric determina-
tion of total bilirubin with the ACA. Comparing this
modification with our diazo modification we conclude
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that the spectrometric method has some practical
advantages for several reasons:
1. The main problem in neonatal bilirubin analysis,
namely hemolysis, is solved in a better way as can be
seen from figure 2.
2. The precision is better as can be seen in table 1, even
if the sample volume is 20 μΐ (also advantageous!).
3. The comparison with two other techniques,
Richterich's spectrometric method and the diazo
method published by Michaelsson et al. is very favour-
able (table 2).
4. Additional reagents are not needed.
Another two points are relevant. As one can see in
figure 1 the calibration graph is linear up to ^t Je^st.
400 μτηοΐ/ΐ which is, clinically speaking, sufficient.
Furthermore as can be seen from table 2 we were not
able to detect differences between samples coming from
babies treated with phototherapy and samples from
babies who were not treated with phototherapy. This
is in accordance with the work ofEbbesen (8). The
correlation coefficients for umbilical cord blood and
peripheral blood analyses are comparable, when using
the Michaelsson technique and the NBIL method. How-
ever, there is a difference in the slopes of the regression
lines (table 2). We cannot give an explanation for this
phenomenon. It is possible that there is a serum matrix
effect.
At the moment no further work is planned to determine
the reason for the observed differences, because the
determination of bilirubin in cord blood is becoming
less important. This is due to the general use, since
1969, of anti-D-immunoglobulin in Holland in cases of
rhesus incompatability (9).
The comparison between R ichterich's technique and the
NBIL method raises the question of accuracy. Although
the coefficient of correlation is excellent (0.99) there is
a difference in result (fig. 3). Work is in progress to try
and solve this problem. One point which may be impor-
tant is that the calculation of the results i {he manil^l
method is based onRichterich's formula with absoff
ances measured on a Beckman DU*2 spectrophotometer
and in the case of the ACA by means of standard
specimens. The same question of accuracy arises in
considering figure 4. The problem is: "hp\v equal" is n
spectrometric determination of bilirubin to a diazo
measurement? The results we gfetaifie W§?§
comparable to each other which is also the conclusion
of Hertz (3) ^ndBlumberger-(\Q).
This brings us to the method of standardization. When
using a diazo reaction, such as the modification described
by Doumas, or the Michaelsson technique, there is no
difference between albumin-based and serum-based
bilirubin standards. This was shown by Doumas (7),
and it is in accordance with our own experience.
Dybkaer, however, ih his spectrometric modification,
advocates suitable serum diluent instead of human
albumin solution (U),
At the present time, for practical reasons, we have chosen
bUirubjin standards in albumin, because their prepara-
tion is easy and reproducible. In addition, preliminary
studies show no appreciable difference between serum-
based and albumin-based calibration graphs in the ACA.
However, it is our intention to study this part in more
detail, not only because ofDybkaer's statements (though
he doesn't mention data), but also because of differences
seen in the preparation of the bilirubin standards. Compar-
ing the Merck product with the N.B.S. bilirubin we noted
that the Merck bilirubin dissolved much slower than the
N.B.S. product. Furthermore the Merck standard is
orange coloured while the N.B.S. standard is brownish
orange. Both differences may be caused by the existence
of isomeric forms and/or the presence of traces of
impurities.
However, the calibration with some commercial sera gave
results which were not acceptable. In the lower range
we measured differences up to 20 μτηοΐ/ΐ and in the
higher range up to 37 μπιοΐ/ΐ.
The turbidity of some samples (Monitrol, Calibrate,
Versatol Pediatric and Hyland) is, in our opinion, one
important cause of these differences.
Summarizing, we now prefer our NBIL modification to
our earlier BBIL solution, with respect to the determina-
tion of neonatal total bilirubin, although the standardiza-
tion needs further investigation. ,
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Das Lehrbuch Pathobiochemie beschreibt
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